We are a product-orientated biopharmaceutical company primarily focused upon the acquisition, development, and marketing of compounds and technologies for the treatment of cancer. Our product pipeline includes Evoltra® (clofarabine) which has marketing approval in both the European Union (“E.U.”) and United States (“U.S.”) for the treatment of pediatric relapsed or refractory acute lymphoblastic leukemia, Modrenal® (trilostane), which has marketing approval in the United Kingdom (“U.K.”) for the treatment of post-menopausal breast cancer following relapse to initial hormone therapy, and other products. On May 29, 2007, we entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Genzyme Corporation, our North American co-development partner for clofarabine (“Genzyme”) and Wichita Bio Corporation, a wholly-owned subsidiary of Genzyme (“Wichita Bio”). We are holding a special meeting of our stockholders to vote on this proposed merger, which is currently scheduled for October 4, 2007. The merger is the second and final step in the proposed acquisition of Bioenvision by Genzyme. The first step was the tender offer for all of the outstanding common stock and all of the outstanding preferred stock of Bioenvision, which expired on July 10, 2007. Pursuant to the tender offer, Wichita Bio purchased 8,398,098 shares of common stock, representing approximately 15.3% of the outstanding shares of our common stock as of the date hereof, and 2,250,000 shares of preferred stock, representing 100% of the outstanding shares of our preferred stock as of the date hereof. Following the tender offer and as of the date hereof, Genzyme beneficially owns approximately 22 % of the outstanding shares of Bioenvision common stock on an as-converted basis including all outstanding shares of Bioenvision preferred stock. If the merger is completed, Wichita Bio, will be merged with and into Bioenvision, we will become a wholly-owned subsidiary of Genzyme and each share of our common stock issued and outstanding immediately before the merger, other than treasury shares, shares for which appraisal rights have been perfected and shares held by Genzyme or Wichita Bio, will automatically be canceled and will cease to exist and will be converted into the right to receive $5.60 in cash, without interest. See "Factors Relating to the Proposed Merger with Genzyme" beginning on page 10.
Company profile
Ticker
BIVN
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Ascot Group Inc
SEC CIK
Corporate docs
IRS number
113375915
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
24 Oct 07
EFFECT
Notice of effectiveness
24 Oct 07
15-12G
Securities registration termination
23 Oct 07
25-NSE
Exchange delisting
23 Oct 07
POS AM
Prospectus update (post-effective amendment)
23 Oct 07
POS AM
Prospectus update (post-effective amendment)
23 Oct 07
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Oct 07
8-K
In the Court of Chancery of the State of Delaware
11 Oct 07
DEFA14A
Additional proxy soliciting materials
11 Oct 07
8-K
Other Events
10 Oct 07
Latest ownership filings
144
Notice of proposed sale of securities
7 Mar 06
144
Notice of proposed sale of securities
28 Feb 06
144
Notice of proposed sale of securities
28 Feb 06
144
Notice of proposed sale of securities
28 Feb 06
144
Notice of proposed sale of securities
28 Feb 06
144/A
Notice of proposed sale of securities (amended)
6 Sep 05
144
Notice of proposed sale of securities
30 Aug 05
144
Notice of proposed sale of securities
26 Aug 05
144
Notice of proposed sale of securities
21 Jul 05
144
Notice of proposed sale of securities
24 Nov 04